Dr. Hua Zhong and Dr. Baohui Han on the Efficacy and Safety of Sacituzumab Govitecan in Extensive-Stage Small Cell Lung Cancer

Dr. Hua Zhong and Dr. Baohui Han on the Efficacy and Safety of Sacituzumab Govitecan in Extensive-Stage Small Cell Lung Cancer

The rapid advancements in modern oncology have introduced numerous breakthrough treatment options for lung cancer, making it one of the fastest-evolving solid tumors. To help clinicians gain an in-depth and comprehensive understanding of major developments in this field, Oncology Frontier has collaborated with Dr. Hua Zhong and Dr. Baohui Han from the Department of Respiratory and Critical Care Medicine at Shanghai Chest Hospital to launch a clinical progress series—"Zhong" Sound "Hui" Words. Through in-depth analyses of high-quality clinical studies in lung cancer, this series aims to enhance clinical decision-making and treatment practices.
ASCO GI 2025 | Dr. Anna Dorothea Wagner:Dual-Target Therapy Shows No Survival Benefit in HER2-Positive Gastric Cancer

ASCO GI 2025 | Dr. Anna Dorothea Wagner:Dual-Target Therapy Shows No Survival Benefit in HER2-Positive Gastric Cancer

The 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI 2025) successfully concluded on January 25. One of the most closely watched presentations at the conference was the release of results from the EORTC-1203—INNOVATION trial (Abstract LBA331), capturing the attention of oncologists worldwide. Oncology Frontier had the exclusive opportunity to interview Dr. Anna Dorothea Wagner, a medical oncologist from Lausanne University Hospital in Switzerland, to discuss the study’s findings. Below is a summary of our conversation.